Innovation has been a defining element of Richter’s strategy since its establishment. Today, with a 1000-strong research and development team in Hungary, the company boasts the Central-Eastern European region’s largest centre for pharmaceutical research. Original research focuses on CNS disorders, with main clinical targets being schizophrenia, anxiety, chronic pain and depression, as well as the treatment of benign gynaecological conditions. Richter is also engaged in the development of generic drugs and chemical processes as well as biotechnology. When compared with other firms in Central Eastern Europe, Richter spends the highest ratio, on average 10 per cent of its revenue, on R&D.